Non-Small Cell Lung Cancer Pipeline Insight, Pipeline Assessment, Pipeline Drug

"Non-Small Cell Lung Cancer Pipeline Insight, 2020" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Non-Small Cell Lung Cancer market. A detailed picture of the Non-Small Cell Lung Cancer pipeline landscape is provided, which includes the disease overview and Non-Small Cell Lung Cancer treatment guidelines.

The assessment part of the report embraces in-depth Non-Small Cell Lung Cancer commercial assessment and clinical assessment of the Non-Small Cell Lung Cancer pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Non-Small Cell Lung Cancer collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

NSCLC report encloses the detailed analysis of Non-Small Cell Lung Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.

The therapies that are approved for the NSCLC treatment are Rozlytrek (Entrectinib), Imfinzi (Durvalumab), Opdivo (Nivolumab), Tecentriq (Atezolizumab), Keytruda (Pembrolizumab), Tafinlar (Dabrafenib) in combination with Mekinist (Trametinib), Tagrisso (osimertinib), Lorbrena/Lorviqua (Lorlatinib), Vizimpro (Dacomitinib), Alunbrig (Brigatinib), Alecensa (Alectinib), Vitrakvi (Larotrectinib), Portrazza (Necitumumab) along with many more.


Non-Small Cell Lung Cancer

Drugs covered in the report are:-

There are several key players robustly involved in developing potential products such as
  • Nazartinib (EGF816)
  • Capmatinib (INC280)
  • Tepmetko (tepotinib)
  • Merestinib
  • JNJ-61186372 (JNJ-6372)
  • Vemurafenib Plus Cobimetinib
  • X-396 (Ensartinib)
  • Tedopi (OSE2101)
  • Selpercatinib (LY3527723/ LOXO-292)
  • SAR408701
  • Braftovi (encorafinib) + Mektovi (binimetinib)
  • PADCEV (enfortumab vedotin/ASG-22ME)
  • Pralsetinib (BLU-667)
  • TAK-788: Canakinumab (ACZ885)
  • Avelumab (Bavencio)
  • Veliparib (ABT-888): Sitravatinib (MGCD516)
  • Tesevatinib
  • Romiplostim: Cabozantinib
  • Sym015
  • AMG 510
  • INCMGA00012 (MGA012)
  • Libtayo (Cemiplimab)
  • Bavituximab
  • M7824 (Bintrafusp alfa)
  • And many others

Request Sample Page @ https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-pipeline-insight

Key Players covered in the report are:-
  • Novartis Pharmaceuticals
  • Merck KGaA
  • Eli Lilly and Company
  • Janssen Research & Development
  • Hoffmann-La Roche
  • Xcovery
  • BeyondSpring Pharmaceuticals
  • OSE Immunotherapeutics
  • Sanofi
  • Pfizer
  • Astellas Pharma
  • Seattle Genetics
  • Blueprint Medicines Corporation
  • Takeda
  • AbbVie
  • Kadmon Corporation
  • Amgen
  • Symphogen
  • Regeneron Pharmaceuticals
  • Peregrine Pharmaceuticals
  • Avid Bioservices
  • GlaxoSmithKline
And many others
The report includes provides in depth analysis historical and forecasted Market Share (%) Distribution of NSCLC, Market Share (%) Distribution of NSCLC by Mutations/Biomarkers, Total Market Size of PD-L1 NSCLC, Total Market Size of BRAF NSCLC, Total Market Size of c-Met, Total Market Size of EGFR, Total Market Size of ALK as well.
Market Driver
NSCLC mARKET DRIVER
Request Sample Page @ https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-pipeline-insight
Market Barrier
NSCLC mARKET barrier
Key Questions Answered
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Non-Small Cell Lung Cancer?
  • What are the key findings pertaining to the Non-Small Cell Lung Cancer epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Non-Small Cell Lung Cancer across the 7MM during the forecast period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Non-Small Cell Lung Cancer?
  • What are the currently available treatments of Non-Small Cell Lung Cancer?
Reasons to buy
  • The Non-Small Cell Lung Cancer Epidemiology report will allow the user to -
    Develop business strategies by understanding the trends shaping and driving the global Non-Small Cell Lung Cancer market
  • Quantify patient populations in the global Non-Small Cell Lung Cancer market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Non-Small Cell Lung Cancer therapeutics in each of the markets covered
  • Understand the magnitude of Non-Small Cell Lung Cancer population by its epidemiology
  • The Non-Small Cell Lung Cancer Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources
Key Assessments
  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Request Sample Page @ https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-pipeline-insight

Table of Contents
1.
Key Insights
2.
Executive Summary of NSCLC
3.
SWOT Analysis of NSCLC
4.
Non-Small Cell Lung Cancer Market Overview at a Glance
5.
NSCLC Disease Background and Overview
6.
NSCLC Diagnosis  
7.
Non-Small Cell Lung Cancer Epidemiology and Patient Population
7.1.
The United States Epidemiology
8.
EU-5 Epidemiology
8.1.
Germany
8.2.
France
8.3.
Italy
8.4.
Spain
8.5.
The United Kingdom
9.
Japan Epidemiology
10.
Non-Small Cell Lung Cancer Current Treatment Practices
11.
Guideline of NSCLC
12.
Unmet Needs of NSCLC
13.
Key Endpoints in NSCLC Clinical Trials
14.
Non-Small Cell Lung Cancer Marketed Therapies
14.1.
Key Cross
14.2.
Rozlytrek (Entrectinib): Hoffmann-La Roche (Genentech)
14.3.
Imfinzi (Durvalumab): AstraZeneca
14.4.
Opdivo (Nivolumab): Bristol-Myers Squibb
14.5.
Tecentriq (Atezolizumab): Genentech/Hoffmann-La Roche
14.6.
Keytruda (Pembrolizumab): Merck
14.7.
Tafinlar(Dabrafenib)in Combination with Mekinist(Trametinib): Novartis
14.8.
Tagrisso(Osimertinib): AstraZeneca
14.9.
Lorbrena/Lorviqua (Lorlatinib): Pfizer
14.10.
Vizimpro(Dacomitinib): Pfizer
14.11.
Alunbrig (Brigatinib): Takeda Pharmaceuticals
14.12.
Alecensa (Alectinib): Hoffmann-La Roche
14.13.
Vitrakvi (Larotrectinib): Bayer Healthcare
14.14.
Portrazza (Necitumumab): Eli Lilly
15.
Non-Small Cell Lung Cancer Emerging Therapies
15.1.
Nazartinib (EGF816): Novartis Pharmaceuticals
15.2.
Capmatinib (INC280): Novartis Pharmaceuticals
15.3.
Tepmetko (tepotinib): Merck KGaA
15.4.
Merestinib: Eli Lilly and Company
15.5.
JNJ-61186372 (JNJ-6372): Janssen Research & Development
15.6.
Lazertinib: Yuhan Corporation/ Janssen Research & Development
15.7.
Vemurafenib Plus Cobimetinib: Hoffmann-La Roche
15.8.
X-396 (Ensartinib): Xcovery
15.9.
Plinabulin: BeyondSpring Pharmaceuticals
15.10.
Tedopi (OSE2101): OSE Immunotherapeutics
15.11.
Selpercatinib (LY3527723/ LOXO-292): Eli Lilly and Company
15.12.
SAR408701: Sanofi
15.13.
Braftovi (encorafinib) + Mektovi (binimetinib): Pfizer
15.14.
PADCEV (enfortumab vedotin/ASG-22ME): Astellas Pharma/Seattle Genetics
15.15.
Pralsetinib (BLU-667): Blueprint Medicines Corporation
15.16.
TAK-788: Takeda
15.17.
Canakinumab (ACZ885): Novartis Pharmaceuticals
15.18.
Avelumab (Bavencio): Merck KGaA and Pfizer
15.19.
Veliparib (ABT-888): AbbVie
15.20.
Sitravatinib (MGCD516): Mirati Therapeutics/Bristol-Myers Squibb/Beigene
15.21.
Tesevatinib: Kadmon Corporation
15.22.
Romiplostim: Amgen
15.23.
Cabozantinib: Exelixis/Ipsen/Takeda
15.24.
Sym015: Symphogen
15.25.
AMG 510: Amgen
15.26.
INCMGA00012 (MGA012): Incyte Corporation/ Zai Lab Limited
15.27.
Libtayo (Cemiplimab): Regeneron Pharmaceuticals
15.28.
Bavituximab: Peregrine Pharmaceuticals/ Avid Bioservices, Inc
15.29.
M7824 (Bintrafusp alfa): GlaxoSmithKline/Merck KGaA
16.
NSCLC Seven Major Market Analysis
17.
PD-L1—Market Size
18.
BRAF Mutation—Market Size
19.
c-MET Mutation—Market Size
20.
EGFR Mutation—Market Size
21.
ALK-Mutation—Market Size
22.
Market Access and Reimbursement of NSCLC Therapies
23.
Market Drivers of NSCLC
24.
Market Barriers of NSCLC
25.
Appendix
26.
DelveInsight Capabilities
27.
Disclaimer
28.
About DelveInsight

Request a Webex Demo to get a walk-through of the report:  https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-market

 Related Reports:

 About DelveInsight
DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical, Bio-Tech and Medical devices companies formulate prudent business decisions for improving their performances to stay ahead of the competitors.

Comments

Post a Comment

Popular posts from this blog

Allergic Conjunctivitis Market to Witness Growth by 2032, Estimates DelveInsight | Grevis Pharmaceutical, Johnson and Johnson, Indoco Remedies, Akron Operating, Alembic Pharmaceuticals, Cipla, Ocular Therapeutics, Novartis, AbbVie, Spectra Vision Care, Teva Pharmaceutical, JAWA Pharmaceuticals, Jabs Biotech, Santen Pharmaceuticals, Ajanta Pharma

(Albany, USA) DelveInsight's " Allergic Conjunctivitis Market Insights, Epidemiology, and Market Forecast-2032 " report delivers an in-depth understanding of Allergic Conjunctivitis, historical and forecasted epidemiology as well as the Allergic Conjunctivitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.   The Allergic Conjunctivitis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Allergic Conjunctivitis market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Allergic Conjunctivitis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Allergic Conjunctivitis market.   Request for a Free Sample Report @ https://www.delveinsight.com/report-store/allergic-conjuncti...
Read more

Top Selling Market Research Reports by DelveInsight

Hearing Aid Devices Market The worldwide market for hearing aid devices had a value of USD 7.01 billion in 2021. It is expected to experience a compound annual growth rate (CAGR) of 5.47% during the forecast period spanning from 2023 to 2028, ultimately reaching USD 9.61 billion by 2028. The surge in demand for hearing aids primarily stems from the increasing prevalence of hearing loss on a global scale, coupled with a growing elderly population. Additionally, the rising exposure to high-frequency sounds leading to noise-induced hearing loss could further boost the hearing aids market. Furthermore, advancements in technology, heightened awareness, and government initiatives related to hearing aid devices are anticipated to drive the global hearing aid devices market forward. Click here: https://www.delveinsight.com/report-store/hearing-aid-devices-market   Cerebral Vein Thrombosis Market Dive deep into Cerebral Vein Thrombosis with DelveInsight's report, 'Cerebral Vei...
Read more

DelveInsight’s Latest and Insightful Market Research Reports

Bronchial Spasms Market DelveInsight's report titled ' Bronchial Spasms Market Insights, Epidemiology, and Market Forecast-2032' provides a comprehensive analysis of Bronchial Spasms, including historical and projected epidemiological data, as well as market trends, in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. This market report on Bronchial Spasms offers insights into current treatment approaches, emerging pharmaceuticals, and the market share of various therapies. It also presents the current and projected market size for Bronchial Spasms from 2019 to 2032 across seven major markets. Additionally, the report discusses the current treatment protocols and algorithms for Bronchial Spasms, along with factors driving and hindering market growth. Furthermore, it highlights unmet medical needs in the Bronchial Spasms landscape, aiming to identify opportunities and evaluate the inherent potential within the Bronchial Spasms market....
Read more